{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:13:21Z","timestamp":1794899601975,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study examined the role of arecoline-induced zinc finger protein 582 (ZNF582) methylation via extracellular vesicles (EVs) in oral squamous cell carcinoma (OSCC) and its effect on PD-L1 expression through the interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>EVs were isolated from SAS and TW2.6 cancer cell lines using ultracentrifugation and characterized using electron microscopy. ZNF582 methylation and protein expression were assessed, with stemness and epithelial-mesenchymal transition (EMT) markers analyzed via Western blotting. T cell populations were evaluated using flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Arecoline-induced ZNF582 methylation via EVs reduced protein expression. ZNF582 knockdown promoted OSCC proliferation, migration, stemness, and EMT, and increased PD-L1 expression, aiding immune evasion via IFIT1. PD-L1 expression was linked to lower CD4+\/CD8\u2009+\u2009T cell ratios in OSCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Arecoline-induced ZNF582 hypermethylation via EVs promotes immune evasion through IFIT1, suggesting a potential therapeutic target for OSCC treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical relevance<\/jats:title>\n                    <jats:p>\n                      Targeting the EV-mediated\n                      <jats:italic>ZNF582<\/jats:italic>\n                      -\n                      <jats:italic>IFIT1<\/jats:italic>\n                      -\n                      <jats:italic>PD-L1<\/jats:italic>\n                      pathway may offer new therapeutic strategies for immune modulation in OSCC patients, especially those with a history of areca nut exposure.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-026-02066-4","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T22:27:12Z","timestamp":1779748032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Arecoline-induced EV-mediated ZNF582 hypermethylation drives IFIT1\u2013PD-L1 immune evasion in oral squamous cell carcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Hui-Hsin","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Pin","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Fong","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Yen-Ping","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2066_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00784-013-1023-3","volume":"18","author":"Y Huang","year":"2014","unstructured":"Huang Y, Peng B, Wu C, et al. DNA methylation of ZNF582 as a biomarker for oral squamous cell carcinoma. Clin Oral Investig. 2014;18:801\u20138. https:\/\/doi.org\/10.1007\/s00784-013-1023-3.","journal-title":"Clin Oral Investig"},{"key":"2066_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13148-015-0077-8","volume":"7","author":"Y Liou","year":"2015","unstructured":"Liou Y, Zhang Y, Liu Y, et al. Comparison of HPV genotyping and methylated ZNF582 as triage for women with equivocal liquid-based cytology results. Clin Epigenetics. 2015;7:50. https:\/\/doi.org\/10.1186\/s13148-015-0077-8.","journal-title":"Clin Epigenetics"},{"key":"2066_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1371\/journal.pone.0041060","volume":"18","author":"R Huang","year":"2012","unstructured":"Huang R, Chang C, Su P, et al. Methylomic analysis identifies epigenetically silenced genes in oral squamous cell carcinoma. Clin Cancer Res. 2012;18:15\u201323. https:\/\/doi.org\/10.1371\/journal.pone.0041060.","journal-title":"Clin Cancer Res"},{"key":"2066_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.oraloncology.2017.05.011","volume":"72","author":"Y Chen","year":"2017","unstructured":"Chen Y, Cheng S, Ko H, et al. ZNF582 methylation and human papillomavirus are associated with oral cancer. Oral Oncol. 2017;72:129\u201337. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.05.011.","journal-title":"Oral Oncol"},{"key":"2066_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/jop.13137","volume":"19","author":"C Chang","year":"2017","unstructured":"Chang C, Ko H, Hsiao S, et al. Hypermethylated ZNF582 in serum as a biomarker for oral cancer. Cancer Biomark. 2017;19:479\u201388. https:\/\/doi.org\/10.1111\/jop.13137.","journal-title":"Cancer Biomark"},{"key":"2066_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oraloncology.2016.09.008","volume":"62","author":"S Cheng","year":"2016","unstructured":"Cheng S, Chang C, Ko H, et al. Hypermethylated ZNF582 and ZNF582 are effective biomarkers for detection of oral dysplasia and oral cancer. Oral Oncol. 2016;62:34\u201343. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.09.008.","journal-title":"Oral Oncol"},{"key":"2066_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/hed.24956","volume":"40","author":"S Cheng","year":"2018","unstructured":"Cheng S, Chang C, Ko H, et al. Hypermethylated ZNF582 and ZNF582 genes in mouth rinse samples as biomarkers for oral dysplasia and oral cancer detection. Head Neck. 2018;40:355\u201368. https:\/\/doi.org\/10.1002\/hed.24956.","journal-title":"Head Neck"},{"key":"2066_CR8","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.oraloncology.2017.11.013","volume":"75","author":"S Cheng","year":"2017","unstructured":"Cheng S, Chang C, Ko H, et al. Hypermethylated ZNF582 and ZNF582 genes in oral scrapings collected from cancer-adjacent normal oral mucosal sites are associated with aggressive progression and poor prognosis of oral cancer. Oral Oncol. 2017;75:169\u201377. https:\/\/doi.org\/10.1016\/j.oraloncology.2017.11.013.","journal-title":"Oral Oncol"},{"key":"2066_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/odi.14399","volume":"72","author":"M Chen","year":"2017","unstructured":"Chen M, Yang H, Ko H, et al. Hypermethylated ZNF582 as an epigenetic biomarker for head and neck cancer. Oral Oncol. 2017;72:153\u20138. https:\/\/doi.org\/10.1111\/odi.14399.","journal-title":"Oral Oncol"},{"key":"2066_CR10","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.3892\/ol.2020.11831","volume":"20","author":"Y Li","year":"2020","unstructured":"Li Y, Guo X, Xing J, et al. Next generation sequencing-based analysis of mitochondrial DNA characteristics in plasma extracellular vesicles of patients with hepatocellular carcinoma. Oncol Lett. 2020;20:2820\u20138. https:\/\/doi.org\/10.3892\/ol.2020.11831.","journal-title":"Oncol Lett"},{"key":"2066_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.oraloncology.2022.105990","volume":"94","author":"H Ko","year":"2019","unstructured":"Ko H, Hsu Y, Kao T, et al. Diagnostic value of ZNF582 DNA methylation as a biomarker for early detection of oral cancer. Oral Oncol. 2019;94:104\u201311. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.105990.","journal-title":"Oral Oncol"},{"key":"2066_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/jop.13137","volume":"50","author":"H Ko","year":"2021","unstructured":"Ko H, Hsu Y, Cheng S, et al. Application of ZNF582 DNA methylation as a biomarker for screening and prognosis of oral cancer. J Oral Pathol Med. 2021;50:226\u201333. https:\/\/doi.org\/10.1111\/jop.13137.","journal-title":"J Oral Pathol Med"},{"key":"2066_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/mp.53.4.165","volume":"53","author":"HK Williams","year":"2000","unstructured":"Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol. 2000;53:165\u201372. https:\/\/doi.org\/10.1136\/mp.53.4.165.","journal-title":"Mol Pathol"},{"key":"2066_CR14","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.3892\/ol.2016.4642","volume":"11","author":"B Huang","year":"2016","unstructured":"Huang B, Lin N, Cheng D, et al. Histone deacetylase inhibitors suppress metastasis in oral squamous cell carcinoma. Oncol Lett. 2016;11:3679\u201384. https:\/\/doi.org\/10.3892\/ol.2016.4642.","journal-title":"Oncol Lett"},{"key":"2066_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2017.08.004","volume":"410","author":"W Li","year":"2017","unstructured":"Li W, Zheng J, Deng J, et al. LncRNA HOTAIR promotes EMT by regulating chromatin remodeling in oral squamous cell carcinoma. Cancer Lett. 2017;410:47\u201355. https:\/\/doi.org\/10.1016\/j.canlet.2017.08.004.","journal-title":"Cancer Lett"},{"key":"2066_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/odi.13946","volume":"29","author":"YC Juan","year":"2023","unstructured":"Juan YC, Su YF, Bai CH, et al. ZNF582 hypermethylation as a prognostic biomarker for malignant transformation of oral lesions. Oral Dis. 2023;29:505\u201314. https:\/\/doi.org\/10.1111\/odi.13946.","journal-title":"Oral Dis"},{"key":"2066_CR17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/nar\/11.4.1213","volume":"11","author":"J Chebath","year":"1983","unstructured":"Chebath J, Merlin G, Metz R, et al. Interferon-induced 56,000 Mr protein and its mRNA in human cells: molecular cloning and partial sequence of the cDNA. Nucleic Acids Res. 1983;11:1213\u201326. https:\/\/doi.org\/10.1093\/nar\/11.4.1213.","journal-title":"Nucleic Acids Res"},{"key":"2066_CR18","doi-asserted-by":"publisher","first-page":"14755","DOI":"10.1016\/S0021-9258(18)30339-7","volume":"258","author":"SJ Gendler","year":"1983","unstructured":"Gendler SJ, Cohen EP, Kim S, et al. Induction of an interferon-induced protein in human cells by human alpha and gamma interferons. J Biol Chem. 1983;258:14755\u201361. https:\/\/doi.org\/10.1016\/S0021-9258(18)30339-7.","journal-title":"J Biol Chem"},{"key":"2066_CR19","doi-asserted-by":"publisher","first-page":"11132","DOI":"10.1128\/JVI.02032-13","volume":"87","author":"H Schmeisser","year":"2013","unstructured":"Schmeisser H, Schopf T, Hentschel J, et al. Interferon-inducible protein with tetratricopeptide repeats 1 (IFIT1) is a novel host restriction factor of influenza A virus. J Virol. 2013;87:11132\u201344. https:\/\/doi.org\/10.1128\/JVI.02032-13.","journal-title":"J Virol"},{"key":"2066_CR20","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1111\/cmi.12170","volume":"15","author":"C Perdomo","year":"2013","unstructured":"Perdomo C, Coudereau D, Kress E, et al. The interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) is an inhibitor of human papillomavirus 16 (HPV16) E6-E7-mediated transformation. Cell Microbiol. 2013;15:1916\u201328. https:\/\/doi.org\/10.1111\/cmi.12170.","journal-title":"Cell Microbiol"},{"key":"2066_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12967-018-1674-5","volume":"16","author":"C Ding","year":"2018","unstructured":"Ding C, Yang J, Yang X, et al. The IFIT family of interferon-stimulated genes: a review. J Transl Med. 2018;16:284. https:\/\/doi.org\/10.1186\/s12967-018-1674-5.","journal-title":"J Transl Med"},{"key":"2066_CR22","doi-asserted-by":"publisher","first-page":"12439","DOI":"10.1128\/JVI.01522-12","volume":"86","author":"A Phelan","year":"2012","unstructured":"Phelan A, Li R, Li G, et al. Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) inhibits hepatitis B virus (HBV) replication. J Virol. 2012;86:12439\u201344. https:\/\/doi.org\/10.1128\/JVI.01522-12.","journal-title":"J Virol"},{"key":"2066_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.yexcr.2018.01.031","volume":"363","author":"R Li","year":"2018","unstructured":"Li R, Wang R, Han Y, et al. IFIT1 promotes pancreatic cancer progression by regulating cell proliferation and apoptosis. Exp Cell Res. 2018;363:172\u20139. https:\/\/doi.org\/10.1016\/j.yexcr.2018.01.031.","journal-title":"Exp Cell Res"},{"key":"2066_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-018-0692-4","volume":"37","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wang H, Zhang L, et al. IFIT1 inhibits breast cancer cell proliferation and invasion. J Exp Clin Cancer Res. 2018;37:29. https:\/\/doi.org\/10.1186\/s13046-018-0692-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"2066_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41419-017-0124-1","volume":"9","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra A, Mao M. PD-1\/PD-L1 blockade: current status and future directions. Cell Death Dis. 2018;9:104. https:\/\/doi.org\/10.1038\/s41419-017-0124-1.","journal-title":"Cell Death Dis"},{"key":"2066_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2015.11.020","volume":"371","author":"Y Han","year":"2016","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: molecular mechanisms and clinical significance. Cancer Lett. 2016;371:177\u201387. https:\/\/doi.org\/10.1016\/j.canlet.2015.11.020.","journal-title":"Cancer Lett"},{"key":"2066_CR27","doi-asserted-by":"publisher","first-page":"35687","DOI":"10.18632\/oncotarget.17002","volume":"8","author":"H Chen","year":"2017","unstructured":"Chen H, Tang C, Chen J, et al. PD-L1 expression in oral squamous cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8:35687\u201397. https:\/\/doi.org\/10.18632\/oncotarget.17002.","journal-title":"Oncotarget"},{"key":"2066_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.sdentj.2018.05.004","volume":"31","author":"O Al-Jubran","year":"2019","unstructured":"Al-Jubran O, Al-Harthi A, Al-Thakafi S, et al. PD-L1 expression in oral squamous cell carcinoma and its correlation with clinicopathological features. Saudi Dent J. 2019;31:181\u20137. https:\/\/doi.org\/10.1016\/j.sdentj.2018.05.004.","journal-title":"Saudi Dent J"},{"key":"2066_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12094-017-1764-8","volume":"20","author":"M Li","year":"2018","unstructured":"Li M, Wu Y, Tang C, et al. PD-L1 expression and its prognostic significance in oral squamous cell carcinoma. Clin Transl Oncol. 2018;20:365\u201371. https:\/\/doi.org\/10.1007\/s12094-017-1764-8.","journal-title":"Clin Transl Oncol"},{"key":"2066_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.12659\/MSM.907848","volume":"24","author":"H Zhang","year":"2018","unstructured":"Zhang H, Chen J, Chen Y, et al. PD-L1 expression and its prognostic value in oral squamous cell carcinoma. Med Sci Monit. 2018;24:709\u201316. https:\/\/doi.org\/10.12659\/MSM.907848.","journal-title":"Med Sci Monit"},{"key":"2066_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/OTT.S156227","volume":"11","author":"W Wu","year":"2018","unstructured":"Wu W, Zhang W, Shi L, et al. PD-L1 expression as a prognostic biomarker in oral squamous cell carcinoma: a meta-analysis. Onco Targets Ther. 2018;11:531\u20139. https:\/\/doi.org\/10.2147\/OTT.S156227.","journal-title":"Onco Targets Ther"},{"key":"2066_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/jop.12608","volume":"47","author":"X Sun","year":"2018","unstructured":"Sun X, Liu Y, Li G, et al. PD-L1 expression in oral squamous cell carcinoma: correlations with clinicopathological features and prognosis. J Oral Pathol Med. 2018;47:178\u201384. https:\/\/doi.org\/10.1111\/jop.12608.","journal-title":"J Oral Pathol Med"},{"key":"2066_CR33","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.18632\/oncotarget.23122","volume":"9","author":"Y Wu","year":"2018","unstructured":"Wu Y, Zheng Z, Li X, et al. PD-L1 expression in oral squamous cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2018;9:2549\u201360. https:\/\/doi.org\/10.18632\/oncotarget.23122.","journal-title":"Oncotarget"},{"key":"2066_CR34","doi-asserted-by":"publisher","first-page":"105990","DOI":"10.1016\/j.oraloncology.2022.105990","volume":"131","author":"S Cheng","year":"2022","unstructured":"Cheng S, Ko H, Chen Y, et al. The hypermethylation of ZNF582 associated with the high PD-L1 expression in oral squamous cell carcinoma. Oral Oncol. 2022;131:105990. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.105990.","journal-title":"Oral Oncol"},{"key":"2066_CR35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/cancers13040545","volume":"13","author":"A Mehdi","year":"2021","unstructured":"Mehdi A, Rabbani SA. Role of methylation in pro- and anti-cancer immunity. Cancers (Basel). 2021;13:545. https:\/\/doi.org\/10.3390\/cancers13040545.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2066_CR36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cancers13040781","volume":"13","author":"D Borsetto","year":"2021","unstructured":"Borsetto D, Tomasoni M, Boscolo-Rizzo P, et al. Prognostic significance of CD4\u2009+\u2009and CD8\u2009+\u2009Tumor-Infiltrating lymphocytes in head and neck squamous cell carcinoma: A Meta-Analysis. Cancers (Basel). 2021;13(4):781. https:\/\/doi.org\/10.3390\/cancers13040781.","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02066-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02066-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T22:27:13Z","timestamp":1779748033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02066-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2066"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02066-4","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the National Taiwan University Hospital Research Ethics Committee (reference number: 201811052RINB). All human subjects provided written informed consent when participating.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}